46.23 USD
+0.63 (+1.38%)
46.23 USD
0 (0%)
Taking everything into account, COLL scores 6 out of 10 in our fundamental rating. COLL was compared to 192 industry peers in the Pharmaceuticals industry. While COLL belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. COLL is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings could make COLL a good candidate for value investing.
1. Profitability
1.1 Basic Checks
In the past year COLL was profitable.
COLL had a positive operating cash flow in the past year.
Of the past 5 years COLL 4 years were profitable.
COLL had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 3.64%, COLL belongs to the best of the industry, outperforming 84.38% of the companies in the same industry.
With an excellent Return On Equity value of 21.27%, COLL belongs to the best of the industry, outperforming 91.67% of the companies in the same industry.
COLL's Return On Invested Capital of 9.10% is amongst the best of the industry. COLL outperforms 88.02% of its industry peers.
COLL had an Average Return On Invested Capital over the past 3 years of 11.08%. This is in line with the industry average of 12.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.64% | ||
| ROE | 21.27% | ||
| ROIC | 9.1% |
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
1.3 Margins
COLL has a Profit Margin of 7.72%. This is amongst the best in the industry. COLL outperforms 83.33% of its industry peers.
In the last couple of years the Profit Margin of COLL has declined.
The Operating Margin of COLL (20.74%) is better than 88.02% of its industry peers.
COLL's Operating Margin has improved in the last couple of years.
COLL has a better Gross Margin (57.22%) than 66.67% of its industry peers.
In the last couple of years the Gross Margin of COLL has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.74% | ||
| PM (TTM) | 7.72% | ||
| GM | 57.22% |
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
2. Health
2.1 Basic Checks
COLL has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, COLL has less shares outstanding
The number of shares outstanding for COLL has been reduced compared to 5 years ago.
COLL has a better debt/assets ratio than last year.
2.2 Solvency
COLL has an Altman-Z score of 1.47. This is a bad value and indicates that COLL is not financially healthy and even has some risk of bankruptcy.
COLL has a Altman-Z score of 1.47. This is comparable to the rest of the industry: COLL outperforms 58.33% of its industry peers.
The Debt to FCF ratio of COLL is 2.79, which is a good value as it means it would take COLL, 2.79 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.79, COLL belongs to the top of the industry, outperforming 90.63% of the companies in the same industry.
A Debt/Equity ratio of 2.71 is on the high side and indicates that COLL has dependencies on debt financing.
The Debt to Equity ratio of COLL (2.71) is worse than 80.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.71 | ||
| Debt/FCF | 2.79 | ||
| Altman-Z | 1.47 |
ROIC/WACC1.03
WACC8.82%
2.3 Liquidity
A Current Ratio of 1.36 indicates that COLL should not have too much problems paying its short term obligations.
The Current ratio of COLL (1.36) is worse than 73.44% of its industry peers.
A Quick Ratio of 1.27 indicates that COLL should not have too much problems paying its short term obligations.
The Quick ratio of COLL (1.27) is worse than 70.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.27 |
3. Growth
3.1 Past
COLL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.73%, which is quite impressive.
Measured over the past years, COLL shows a very strong growth in Earnings Per Share. The EPS has been growing by 154.78% on average per year.
The Revenue has grown by 26.34% in the past year. This is a very strong growth!
COLL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.31% yearly.
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%
3.2 Future
Based on estimates for the next years, COLL will show a decrease in Earnings Per Share. The EPS will decrease by -1.58% on average per year.
The Revenue is expected to grow by 3.62% on average over the next years.
EPS Next Y40.67%
EPS Next 2Y14.84%
EPS Next 3Y5.61%
EPS Next 5Y-1.58%
Revenue Next Year19.45%
Revenue Next 2Y11.07%
Revenue Next 3Y4.6%
Revenue Next 5Y3.62%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 6.43 indicates a rather cheap valuation of COLL.
94.79% of the companies in the same industry are more expensive than COLL, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.15. COLL is valued rather cheaply when compared to this.
Based on the Price/Forward Earnings ratio of 5.43, the valuation of COLL can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of COLL indicates a rather cheap valuation: COLL is cheaper than 95.83% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of COLL to the average of the S&P500 Index (36.12), we can say COLL is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.43 | ||
| Fwd PE | 5.43 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of COLL indicates a rather cheap valuation: COLL is cheaper than 97.92% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of COLL indicates a rather cheap valuation: COLL is cheaper than 95.31% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.05 | ||
| EV/EBITDA | 4.82 |
4.3 Compensation for Growth
COLL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of COLL may justify a higher PE ratio.
PEG (NY)0.16
PEG (5Y)N/A
EPS Next 2Y14.84%
EPS Next 3Y5.61%
5. Dividend
5.1 Amount
No dividends for COLL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
46.23
+0.63 (+1.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners116.73%
Inst Owner Change0.64%
Ins Owners1.56%
Ins Owner Change-0.63%
Market Cap1.46B
Revenue(TTM)757.07M
Net Income(TTM)58.44M
Analysts81.82
Price Target47.74 (3.27%)
Short Float %17.38%
Short Ratio12.19
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.9%
Min EPS beat(2)1.88%
Max EPS beat(2)7.92%
EPS beat(4)4
Avg EPS beat(4)6.15%
Min EPS beat(4)1.88%
Max EPS beat(4)12.85%
EPS beat(8)7
Avg EPS beat(8)12.99%
EPS beat(12)9
Avg EPS beat(12)-15.06%
EPS beat(16)10
Avg EPS beat(16)-21.97%
Revenue beat(2)2
Avg Revenue beat(2)5.22%
Min Revenue beat(2)1.9%
Max Revenue beat(2)8.53%
Revenue beat(4)3
Avg Revenue beat(4)2.75%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)8.53%
Revenue beat(8)4
Avg Revenue beat(8)0.8%
Revenue beat(12)6
Avg Revenue beat(12)0.28%
Revenue beat(16)8
Avg Revenue beat(16)-3.75%
PT rev (1m)4.93%
PT rev (3m)5.88%
EPS NQ rev (1m)7.86%
EPS NQ rev (3m)8.88%
EPS NY rev (1m)0%
EPS NY rev (3m)29.1%
Revenue NQ rev (1m)5.8%
Revenue NQ rev (3m)4%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)0.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.43 | ||
| Fwd PE | 5.43 | ||
| P/S | 1.93 | ||
| P/FCF | 5.05 | ||
| P/OCF | 5.02 | ||
| P/B | 5.32 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.82 |
EPS(TTM)7.19
EY15.55%
EPS(NY)8.51
Fwd EY18.4%
FCF(TTM)9.15
FCFY19.8%
OCF(TTM)9.2
OCFY19.91%
SpS23.95
BVpS8.69
TBVpS-18.86
PEG (NY)0.16
PEG (5Y)N/A
Graham Number37.5
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.64% | ||
| ROE | 21.27% | ||
| ROCE | 13.6% | ||
| ROIC | 9.1% | ||
| ROICexc | 12.09% | ||
| ROICexgc | N/A | ||
| OM | 20.74% | ||
| PM (TTM) | 7.72% | ||
| GM | 57.22% | ||
| FCFM | 38.21% |
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
ROICexc(3y)16.99%
ROICexc(5y)14.94%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)16.56%
ROCE(5y)13.94%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y15.58%
ROICexc growth 5YN/A
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.71 | ||
| Debt/FCF | 2.79 | ||
| Debt/EBITDA | 1.94 | ||
| Cap/Depr | 0.72% | ||
| Cap/Sales | 0.21% | ||
| Interest Coverage | 2.17 | ||
| Cash Conversion | 75.92% | ||
| Profit Quality | 495.01% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.27 | ||
| Altman-Z | 1.47 |
F-Score7
WACC8.82%
ROIC/WACC1.03
Cap/Depr(3y)142.93%
Cap/Depr(5y)207.67%
Cap/Sales(3y)41.34%
Cap/Sales(5y)49.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
EPS Next Y40.67%
EPS Next 2Y14.84%
EPS Next 3Y5.61%
EPS Next 5Y-1.58%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%
Revenue Next Year19.45%
Revenue Next 2Y11.07%
Revenue Next 3Y4.6%
Revenue Next 5Y3.62%
EBIT growth 1Y-18.86%
EBIT growth 3Y89.16%
EBIT growth 5YN/A
EBIT Next Year149%
EBIT Next 3Y27.45%
EBIT Next 5Y18.85%
FCF growth 1Y8.55%
FCF growth 3Y25.98%
FCF growth 5Y56.88%
OCF growth 1Y8.67%
OCF growth 3Y25.54%
OCF growth 5Y49.12%
COLLEGIUM PHARMACEUTICAL INC / COLL FAQ
What is the ChartMill fundamental rating of COLLEGIUM PHARMACEUTICAL INC (COLL) stock?
ChartMill assigns a fundamental rating of 6 / 10 to COLL.
Can you provide the valuation status for COLLEGIUM PHARMACEUTICAL INC?
ChartMill assigns a valuation rating of 9 / 10 to COLLEGIUM PHARMACEUTICAL INC (COLL). This can be considered as Undervalued.
What is the profitability of COLL stock?
COLLEGIUM PHARMACEUTICAL INC (COLL) has a profitability rating of 8 / 10.
Can you provide the financial health for COLL stock?
The financial health rating of COLLEGIUM PHARMACEUTICAL INC (COLL) is 5 / 10.